Imagine if we could build a tiny, synthetic 'robot' bubble that acts like a soldier in your blood. Instead of using a patient's own expensive and fragile cells, these man-made bubbles are programmed to find and destroy cancer cells. It is like replacing a custom-made, artisanal medicine with a standardized, mass-produced version that works just as well.
Current CAR-T therapies are too expensive, complex to manufacture, and suffer from donor-dependency and immune rejection. This creates a bottleneck in treating chemoresistant blood cancers.
A synthetic cell platform using Giant Unilamellar Vesicles (GUVs) equipped with tumor-recognizing receptors and cytotoxic proteins.
If you are a cell therapy developer dealing with the high cost and complexity of donor-dependent CAR-T production — this project developed a synthetic cell substitute that allows for mass production of an off-the-shelf therapeutic solution.
If you are a treatment provider dealing with immune rejection and variability in biological cell sources — this project developed artificial T-cells that bypass cell-derived components to ensure a safer and more consistent product.
If you are a platform company dealing with the instability of synthetic vesicles — this project developed a reinforced GUV cytoskeletal framework that ensures mechanical stability for cytotoxic functions.
Based on available project data, the technology replaces donor-dependent biological cells with mass-produced synthetic vesicles, removing the expensive and complex manufacturing processes associated with allogeneic CAR-T therapies.
The project aims to create a scalable, on-demand artificial T-cell substitute that enables mass production, though specific industrial throughput numbers are not yet provided.
Based on available project data, the project is in its initial phase of developing recombinant proteins and GUV structures; specific patent or licensing details are not mentioned.
The project operates on a five-year timeline from 2024-02-01 to 2029-01-31 to advance toward a clinically viable platform.
Based on available project data, it is designed as an off-the-shelf substitute for CAR-T cells, potentially simplifying the logistics of patient-specific cell engineering.
The consortium is purely academic and research-driven, consisting of 4 partners from 4 countries (BE, IT, NL, PL). With 3 universities and 1 research organization, there is a 0% industry ratio, indicating the project is currently focused on high-risk fundamental discovery rather than immediate commercial deployment.
Contact the Katholieke Universiteit Leuven research office regarding the ArTCell project.
Contact us to identify potential industrial partners for the upcoming validation phases of ArTCell.
